MeiraGTx Holdings PLC closed its IPO to raise gross proceeds of $75 million.
The New York-based MeiraGTx sold 5 million ordinary shares at $15 per share.
The gene therapy company's ordinary shares started trading on the Nasdaq Global Select Market on June 8 under the ticker symbol MGTX.
Bank of America Merrill Lynch, Barclays and Evercore ISI acted as joint book-running managers for the offering, with Chardan as lead manager.
